Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mentor completes enrollment in Phase I cervical dystonia trial
Joshua Levine, president and CEO of Mentor, said: “We are very excited about the completion of subject enrollment in this clinical trial. We are now planning the next
Joshua Levine, president and CEO of Mentor, said: “We are very excited about the completion of subject enrollment in this clinical trial. We are now planning the next
The SILK-Aß assay refers to the use of stable isotope labeling and tandem mass spectrometry for the measurement of the kinetics, or metabolism, of amyloid-beta. Amyloid-beta is a
The objectives of this trial are to assess safety, tolerability, and pharmacokinetics following ascending single oral doses of ANA598 in healthy volunteers. Approximately 40 healthy subjects will participate
A total of 36 evaluable patients with stable chronic asthma were enrolled in the randomized, multi-center, double-blind, Phase II, three-period, crossover trial, which was designed to explore the
Patheon KK will operate from a newly established business office located in the Nihonbashi district of central Tokyo and will support Patheon’s business requirements in the region. Patheon
Mr Oberlton recently served as chief information or technology officer for Atlanta Public Schools from 2004 to 2007. Mr Oberlton brings extensive experience in large scale business systems
Lannett will receive finished product from Banner Pharmacaps, under a previously announced supply agreement. Banner received approval from the FDA of its abbreviated new drug application last week
Of these seven Phase III studies two are open and enrolling, and five are planned to begin by the end of 2008. These trials involve three different compounds:
Aduro will focus on the development of its proprietary and minimally invasive NT and TNT cancer therapies, which use patented iron oxide nanoparticles to target and kill solid
In the Activate study, median survival time was 26 months (95% CI: 21.6, infinity) and median time-to-progression (TTP) was 14.2 months. Median survival in a historical matched cohort